New fusion peptide comprising a coupling of a silencing domain with small molecule peptide aptamer, is androgen receptor inhibitor, useful to treat prostate cancer and benign prostatic hyperplasia
Fusion peptide (I) comprising a coupling of a silencing domain with small molecule peptide aptamer, for the inhibition of androgen receptor, is new. - ACTIVITY : Cytostatic. - MECHANISM OF ACTION : Androgen receptor inhibitor.
Attached files:Patents:DE 102,008,014,882
Type of Offer:
Sale
« More Biotech Patents